Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Maravai Lifesciences Hldgs I (MRVI)

157 + Investors. Track Smart Money conviction in MRVI. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -1
Streak
1Q ▼
Buyers last Q
50%

Smart Money Signals — MRVI

Based on 159 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their MRVI positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 74% of 3.0Y peak

74% of all-time peak
159 funds currently hold this stock — 74% of the 3.0-year high of 215 funds (reached 2024 Q3). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
📉

Outflows — 15% fewer funds vs a year ago

fund count last 6Q
29 fewer hedge funds hold MRVI compared to a year ago (-15% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.
🟡

Slight buying edge — 50% buying

80 buying80 selling
Last quarter: 80 funds bought or added vs 80 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
➡️

Steady new buyers — ~26 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 18 → 30 → 27 → 26. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

58% of holders stayed for 2+ years

■ 58% conviction (2yr+) ■ 23% medium ■ 19% new
93 out of 159 hedge funds have held MRVI for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
📈

Growing discovery — still being found

46 → 18 → 30 → 27 → 26 new funds/Q
New funds entering each quarter: 18 → 30 → 27 → 26. A growing number of institutions are discovering MRVI each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 70% veterans vs 20% newcomers

■ 70% veterans ■ 10% 1-2yr ■ 20% new
Entry-cohort mix of 165 holders: 116 (70%) are 2+ year veterans, 16 entered 1–2 years ago, and 33 (20%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
📋

Smaller funds dominant — 19% AUM from top-100

19% from top-100 AUM funds
40 of 158 holders rank in the top 100 by AUM, but together hold only 19% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
2.2
out of 10
Low Exit Risk
Exit risk score 2.2/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — MRVI

In 2026 Q1, 80 hedge funds were net buyers of MRVI (26 opened a new position, 54 added to an existing one), while 80 reduced or exited (53 trimmed, 27 sold completely) — a 50% buyer ratio, indicating a slight buying edge. Net fund flow last quarter: -1 funds (more exits than new entries). Total institutional holders: 159.

Hedge Fund Ownership: MRVI

How many hedge funds hold MRVI — quarterly history vs. share price
Quarterly hedge fund ownership of MRVI vs. share price

Market Analysis: MRVI

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: MRVI

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Maravai Lifesciences Hldgs I (MRVI) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much MRVI has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 79d ago
MRVI
+83.6%
XLV
+2.1%

MRVI outperformed XLV by +81.5% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 34d ago
MRVI
+25.2%
XLV
+3.2%

Since the filing became public, MRVI outperformed XLV by +22.0% .

Interpretation: The stock has meaningfully outrun its sector. The trade has partially played out; entry is at a premium to the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

19 top-rated funds 3 high-conviction
Consensus
5.6
/ 10
breadth
×
Elite
3.5
/ 10
conviction
Hedge Fund Positioning: MRVI
157 + Investors

Track Smart Money conviction in MRVI. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 157 160 -1.88%
13F Shares 123M 125M -1.59%
Total Value $344M $405M -15.24%
New Positions 24 27 -3
Increased Positions 55 44 +11
Closed Positions 27 24 +3
Reduced Positions 50 58 -8
Total Calls 4 4 -
Total Puts 3 2 50.0%
PUT/CALL Ratio 0.75 0.5 Neutral

Statistics: MRVI

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

157 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in MRVI. Verified SEC 13F-HR filings.

QUARTER:
Top 25 MRVI holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Brummer Multi-Strategy AB 8.95% 759,743 $2.2M
2 12 West Capital Management LP 3.47% 7,260,195 $20.5M
3 Tejara Capital Ltd 3.26% 3,495,187 $9.9M
4 Monaco Asset Management SAM 1.79% 3,421,020 $9.7M
5 Gtcr LLC 1.51% 20,150,005 $57.0M
6 Braidwell LP 0.97% 10,240,164 $29.0M
7 Philosophy Capital Management LLC 0.46% 2,637,117 $7.5M
8 General American Investors Co Inc 0.32% 1,716,193 $4.9M
9 Alpine Peaks Capital, LP 0.29% 100,000 $283K
10 Epacria Capital Partners, LLC 0.22% 100,078 $283K
11 VARCOV Co. 0.17% 161,685 $458K
12 Delta Investment Management, LLC 0.16% 307,371 $870K
13 Capricorn Fund Managers Ltd 0.15% 339,727 $961K
14 Alpha Wealth Funds, LLC 0.14% 72,000 $207K
15 Symmetry Investments LP 0.11% 359,561 $1.0M
16 Systematic Financial Management LP 0.10% 1,484,539 $4.2M
17 Nano Cap New Millennium Growth Fund L P 0.09% 35,000 $99K
18 PenderFund Capital Management Ltd. 0.09% 205,000 $580K
19 EntryPoint Capital, LLC 0.07% 85,203 $241K
20 Royce & Associates LP 0.05% 1,808,448 $5.1M
21 R Squared Ltd 0.04% 27,394 $78K
22 Quinn Opportunity Partners LLC 0.04% 265,070 $750K
23 First Pacific Advisors, LP 0.04% 884,883 $2.5M
24 Mackenzie Financial Corp 0.02% 6,306,425 $17.8M
25 Renaissance Technologies LLC 0.02% 4,264,689 $12.1M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Maravai Lifesciences Hldgs I (MRVI)

What does the Smart Money Trend signal show for MRVI?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their MRVI positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for MRVI?

Slight buying edge — 50% buying: Last quarter: 80 funds bought or added vs 80 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for MRVI holders?

Smaller funds dominant — 19% AUM from top-100: 40 of 158 holders rank in the top 100 by AUM, but together hold only 19% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held MRVI?

58% of holders stayed for 2+ years: 93 out of 159 hedge funds have held MRVI for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Maravai Lifesciences Hldgs I (MRVI) following the 2026 Q1 hedge fund 13F filings?

As of today, MRVI has moved +25.2% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.2% for the XLV sector ETF — an outperformance of +22.0%. Since the quarter end (March 31, 2026), MRVI has gained +83.6% vs +2.1% for XLV. The stock has meaningfully outrun its sector. The trade has partially played out; entry is at a premium to the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →